What's Happening?
Precise Bio, an Israeli regenerative medicine company with operations in North Carolina, is developing 3D-printed corneas to address the global shortage of transplantable corneal tissue. Last year, the company achieved a significant milestone by providing
a patient with the first-ever corneal implant made solely from human cells grown in a lab. This technology utilizes tissue from a single donor cornea to generate enough cells to fabricate over 400 new corneas through sophisticated laboratory culture techniques and 3D bioprinting. The resulting transparent, layered structure mimics a healthy, natural cornea. An early-stage Phase I trial is currently underway in Israel to evaluate the safety of this technique in human patients. The company reports that the first patient, who had been legally blind for 14 years due to pseudophakic bullous keratopathy, has shown significant visual recovery, being able to read menus and subtitles within weeks of the transplant. Five patients have received the new transplants so far, with visual recovery similar to traditional corneal transplants.
Why It's Important?
This development is critically important for global public health, particularly in the U.S. and other regions facing a severe shortage of donor corneas. Currently, for every cornea transplant performed worldwide, approximately 70 people remain without one, with an estimated 12 to 15 million individuals in need of a transplant lacking access to donor tissue. Precise Bio's approach has the potential to eliminate this shortage by creating a scalable and on-demand supply of corneas. Beyond availability, the bioprinted corneas offer several advantages, including easier transplantation due to unique mechanical properties that shorten operating times, and a higher cell density (over 4,000 cells per square millimeter compared to 2,000-2,500 in standard donor tissue), which is expected to lead to superior optical outcomes. Additionally, the manufacturing process allows for comprehensive quality control and testing for viruses and fungi, potentially reducing risks associated with traditional donor tissues. This innovation could significantly improve the quality of life for millions suffering from corneal blindness.
What's Next?
Precise Bio is continuing its Phase I trial in Israel, planning to transplant an additional 10 patients by the end of the year and complete the trial in 2026. Following the completion of Phase I, the company intends to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct more advanced studies, primarily in the U.S., while also continuing clinical sites in Europe and Israel and exploring high-demand regions like India. Extended studies planned for 2027 will include patients with other health indications. Precise Bio anticipates commercial distribution of its bioprinted corneas in the U.S. by 2030, followed by expansion into Europe and other regions. The company is also working on developing longer cryopreservation methods for the tissue to facilitate global shipping and on-demand supply.
Beyond the Headlines
The advancement of 3D bioprinting for organs like the cornea represents a profound shift in regenerative medicine, moving beyond traditional organ donation models. This technology raises deeper questions about the future of personalized medicine, where tissues and organs could potentially be custom-made for patients, reducing issues of immune rejection and supply chain limitations. The ability to precisely define cell density and structure in bioprinted tissues could lead to outcomes superior to natural tissues, challenging existing medical paradigms. Ethically, while addressing the critical shortage of donor tissues, this technology also opens discussions about the sourcing of initial cells, the long-term implications of synthetic biological materials in the human body, and equitable access to such advanced treatments globally. The success of this approach could pave the way for bioprinting other complex tissues and organs, fundamentally transforming transplant medicine and extending human lifespan and quality of life.
